Artisan Partners Limited Partnership Decreases Position in Celcuity, Inc. $CELC

Artisan Partners Limited Partnership lessened its stake in Celcuity, Inc. (NASDAQ:CELC) by 11.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 401,678 shares of the company’s stock after selling 52,968 shares during the quarter. Artisan Partners Limited Partnership owned 1.03% of Celcuity worth $5,362,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the company. AlphaQuest LLC boosted its position in shares of Celcuity by 176.3% during the 2nd quarter. AlphaQuest LLC now owns 7,087 shares of the company’s stock worth $95,000 after acquiring an additional 4,522 shares in the last quarter. Perkins Capital Management Inc. purchased a new position in Celcuity in the first quarter valued at approximately $115,000. Tema Etfs LLC purchased a new position in Celcuity in the first quarter valued at approximately $158,000. Corton Capital Inc. acquired a new stake in Celcuity during the second quarter worth approximately $175,000. Finally, Creative Planning purchased a new stake in shares of Celcuity during the 2nd quarter worth approximately $177,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Trading Up 3.7%

NASDAQ:CELC opened at $97.50 on Friday. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $101.03. The business’s 50 day moving average is $65.17 and its two-hundred day moving average is $39.65. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The company has a market cap of $4.51 billion, a PE ratio of -26.57 and a beta of 0.72.

Celcuity (NASDAQ:CELC) last posted its earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.13. On average, analysts predict that Celcuity, Inc. will post -2.62 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Stifel Nicolaus raised their price objective on Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a research note on Sunday, October 26th. Needham & Company LLC set a $95.00 target price on shares of Celcuity in a research report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, October 8th. Finally, Craig Hallum increased their price target on shares of Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $97.00.

Insider Activity

In related news, Director Richard E. Buller sold 3,900 shares of Celcuity stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $96.73, for a total value of $377,247.00. Following the transaction, the director owned 7,260 shares of the company’s stock, valued at approximately $702,259.80. This trade represents a 34.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.77% of the stock is owned by company insiders.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.